Kamada Announces Q2 and H1 2025 Financial Results on August 13, 2025.
ByAinvest
Thursday, Aug 7, 2025 7:14 pm ET1min read
KMDA--
Kamada Ltd. specializes in rare and serious conditions through plasma-derived products and is a leader in the specialty plasma-derived therapies field. The company's strategy focuses on driving profitable growth through four primary growth pillars: organic growth from commercial activities, securing new business development opportunities, expanding plasma collection operations, and advancing product candidate development [2].
Investors and financial professionals are encouraged to participate in the conference call to gain insights into Kamada Ltd.'s financial performance and strategic direction for the year. The conference call can be accessed by dialing 1-877-413-7208 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8555 (International) using the conference I.D. 13754604. The call will also be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1726126&tp_key=61b4d50ef5 [3].
References:
[1] https://www.stocktitan.net/news/KMDA/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-eqat81hr403r.html
[2] https://www.biospace.com/press-releases/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-financial-results-on-august-13-2025
[3] https://www.kamada.com/news/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-financial-results-on-august-13-2025/
Kamada Ltd. will release its Q2 and H1 2025 financial results on August 13, 2025, prior to U.S. market opening. A conference call for investors will be held at 8:30 AM ET on the same day, with access via phone or webcast. The company aims to enhance its product portfolio through collaborations and acquisitions, and is focused on commercialization, product lifecycle management, and expanding plasma collection operations in the U.S.
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial-stage global biopharmaceutical company, will release its Q2 and H1 2025 financial results on August 13, 2025, prior to the U.S. market open. The company will host an investment community conference call at 8:30 AM ET on the same day to discuss these results and take questions from shareholders and other interested parties [1].Kamada Ltd. specializes in rare and serious conditions through plasma-derived products and is a leader in the specialty plasma-derived therapies field. The company's strategy focuses on driving profitable growth through four primary growth pillars: organic growth from commercial activities, securing new business development opportunities, expanding plasma collection operations, and advancing product candidate development [2].
Investors and financial professionals are encouraged to participate in the conference call to gain insights into Kamada Ltd.'s financial performance and strategic direction for the year. The conference call can be accessed by dialing 1-877-413-7208 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8555 (International) using the conference I.D. 13754604. The call will also be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1726126&tp_key=61b4d50ef5 [3].
References:
[1] https://www.stocktitan.net/news/KMDA/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-eqat81hr403r.html
[2] https://www.biospace.com/press-releases/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-financial-results-on-august-13-2025
[3] https://www.kamada.com/news/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-financial-results-on-august-13-2025/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet